Idiotypic replica of an anti-human tumor-associated antigen monoclonal antibody. Analysis of monoclonal Ab1 and Ab3 fine specificity. 1989

G Viale, and G Flamini, and F Grassi, and R Buffa, and P G Natali, and M Pelagi, and F Leoni, and S Ménard, and A G Siccardi
Dipartimento di Biologia e Genetica per le Scienze Mediche, Università degli Studi, Milano, Italy.

CaMBr1 is a tissue-specific and tumor-associated saccharidic epitope, defined by mAb MBr1 (Ab1), expressed on glycoconjugates of the human mammary carcinoma cell line MCF-7 and of normal and neoplastic mammary epithelial cells. An anti-anti-idiotypic monoclonal Ab3, 2G-3, identifying a human breast tumor associated antigen, was raised by using as immunogen a mouse anti-idiotypic monoclonal Ab2, A3B10, which behaves as the internal image of CaMBr1. mAb 2G-3, as well as MBr1, defines a saccharidic epitope on glycoconjugates extracted from MCF-7 cells and shows MBr1-like reactivity on normal and neoplastic-tissues. Experimental evidence, however, suggests that the fine immunoreactivity of the two antibodies is not identical, because MBr1 has a preferential reactivity with glycolipids and 2G-3 with glycoproteins. We suggest that a possible biologic explanation for our findings could reside in the nature of the immunogens used to raise the two mAb (glycolipid vs protein "internal image").

UI MeSH Term Description Entries
D007106 Immune Sera Serum that contains antibodies. It is obtained from an animal that has been immunized either by ANTIGEN injection or infection with microorganisms containing the antigen. Antisera,Immune Serums,Sera, Immune,Serums, Immune
D007130 Immunoglobulin Idiotypes Unique genetically-controlled determinants present on ANTIBODIES whose specificity is limited to a single group of proteins (e.g., another antibody molecule or an individual myeloma protein). The idiotype appears to represent the antigenicity of the antigen-binding site of the antibody and to be genetically codetermined with it. The idiotypic determinants have been precisely located to the IMMUNOGLOBULIN VARIABLE REGION of both immunoglobin polypeptide chains. Idiotypes, Immunoglobulin,Ig Idiotypes,Idiotype, Ig,Idiotype, Immunoglobulin,Idiotypes, Ig,Ig Idiotype,Immunoglobulin Idiotype
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D008807 Mice, Inbred BALB C An inbred strain of mouse that is widely used in IMMUNOLOGY studies and cancer research. BALB C Mice, Inbred,BALB C Mouse, Inbred,Inbred BALB C Mice,Inbred BALB C Mouse,Mice, BALB C,Mouse, BALB C,Mouse, Inbred BALB C,BALB C Mice,BALB C Mouse
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D002474 Cell-Free System A fractionated cell extract that maintains a biological function. A subcellular fraction isolated by ultracentrifugation or other separation techniques must first be isolated so that a process can be studied free from all of the complex side reactions that occur in a cell. The cell-free system is therefore widely used in cell biology. (From Alberts et al., Molecular Biology of the Cell, 2d ed, p166) Cellfree System,Cell Free System,Cell-Free Systems,Cellfree Systems,System, Cell-Free,System, Cellfree,Systems, Cell-Free,Systems, Cellfree
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006825 Hybridomas Cells artificially created by fusion of activated lymphocytes with neoplastic cells. The resulting hybrid cells are cloned and produce pure MONOCLONAL ANTIBODIES or T-cell products, identical to those produced by the immunologically competent parent cell. Hybridoma
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000888 Antibodies, Anti-Idiotypic Antibodies which react with the individual structural determinants (idiotopes) on the variable region of other antibodies. Anti-Antibodies,Anti-Idiotype Antibodies,Antibodies, Internal Image,Antigamma Globulin Antibodies,Antiglobulins,Anti Antibodies,Anti-gamma Globulin Antibodies,Anti Idiotype Antibodies,Anti gamma Globulin Antibodies,Anti-Idiotypic Antibodies,Antibodies, Anti,Antibodies, Anti Idiotypic,Antibodies, Anti-Idiotype,Antibodies, Anti-gamma Globulin,Antibodies, Antigamma Globulin,Globulin Antibodies, Anti-gamma,Globulin Antibodies, Antigamma,Image Antibodies, Internal,Internal Image Antibodies

Related Publications

G Viale, and G Flamini, and F Grassi, and R Buffa, and P G Natali, and M Pelagi, and F Leoni, and S Ménard, and A G Siccardi
January 2002, Journal of clinical laboratory analysis,
G Viale, and G Flamini, and F Grassi, and R Buffa, and P G Natali, and M Pelagi, and F Leoni, and S Ménard, and A G Siccardi
May 1994, International journal of cancer,
G Viale, and G Flamini, and F Grassi, and R Buffa, and P G Natali, and M Pelagi, and F Leoni, and S Ménard, and A G Siccardi
July 1993, European journal of immunology,
G Viale, and G Flamini, and F Grassi, and R Buffa, and P G Natali, and M Pelagi, and F Leoni, and S Ménard, and A G Siccardi
August 1991, Hybridoma,
G Viale, and G Flamini, and F Grassi, and R Buffa, and P G Natali, and M Pelagi, and F Leoni, and S Ménard, and A G Siccardi
June 2001, Clinical and experimental medicine,
G Viale, and G Flamini, and F Grassi, and R Buffa, and P G Natali, and M Pelagi, and F Leoni, and S Ménard, and A G Siccardi
March 1989, Journal of immunology (Baltimore, Md. : 1950),
G Viale, and G Flamini, and F Grassi, and R Buffa, and P G Natali, and M Pelagi, and F Leoni, and S Ménard, and A G Siccardi
January 1986, Annales de l'Institut Pasteur. Immunology,
G Viale, and G Flamini, and F Grassi, and R Buffa, and P G Natali, and M Pelagi, and F Leoni, and S Ménard, and A G Siccardi
September 1993, Cancer immunology, immunotherapy : CII,
G Viale, and G Flamini, and F Grassi, and R Buffa, and P G Natali, and M Pelagi, and F Leoni, and S Ménard, and A G Siccardi
August 1991, Journal of immunology (Baltimore, Md. : 1950),
G Viale, and G Flamini, and F Grassi, and R Buffa, and P G Natali, and M Pelagi, and F Leoni, and S Ménard, and A G Siccardi
May 1985, Journal of immunology (Baltimore, Md. : 1950),
Copied contents to your clipboard!